MAPT and Cognitive impairment: It attenuates cognitive impairment in APP/PS1 model mice by increasing the level of mitophagy and phagocytosis in microglia, decreasing the levels of Aβ1-42 and Aβ1-40, decreasing tau hyperphosphorylation, and inhibiting neuroinflammation via the PINK1/parkin signaling pathway or the DCT-1-dependent pathway.